July 10, 2025

HHS Scraps Preventive Care Panel Meeting

HHS unexpectedly canceled a meeting of the U.S. Preventive Services Task Force, prompting fears it may be dismantled following similar moves by Secretary Robert F. Kennedy Jr. at other federal health agencies.

Conexiant

July 09, 2025

Once-Weekly Combo Injection Cuts Weight by 20% 

A large 68-week clinical trial found that a once-weekly combination injection of cagrilintide and semaglutide led to significant and sustained weight loss in adults with overweight or obesity, with over half achieving at least 20% weight reduction.

Conexiant

July 08, 2025

Orforglipron Lowers A1c, Weight in T2D Patients 

A 40-week trial presented at ADA's 85th Scientific Sessions showed that daily oral orforglipron significantly lowered blood sugar and body weight in adults with early type 2 diabetes.

Conexiant

June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

November 17, 2023

FDA Approves Capivasertib With Fulvestrant for Breast Cancer

On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or m...

The ASCO Post

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

August 01, 2024

Tirzepatide Reduces Heart Failure Risk by 38% in Clinical Trial

Results from a trial reveal that Eli Lilly's tirzepatide, a weight loss drug, reduces the risk of heart failure outcomes by 38% compared to a placebo for obese adults, with significant weight loss and improved symptoms. Novo Nordisk's Wegovy also shows promise in reducing heart failure symptoms.

Reuters

July 25, 2024

Senate Investigates Bankruptcy of Hospital Chain: CEO Subpoenaed

The U.S. Senate Committee is calling the CEO of Steward Health to testify about alleged corporate greed and financial mismanagement amid the company's bankruptcy.

Reuters

September 09, 2024

FDA Lifts Hold on Low Blood Sugar Treatment

Rezolute Inc has received FDA approval to proceed with its late-stage trial for a new treatment addressing low blood sugar in individuals with congenital hyperinsulinism, with potential U.S. enrollment expected to start in early 2025.

Reuters